Predicting Drug–Drug Interactions: An FDA Perspective
Open Access
- 6 May 2009
- journal article
- review article
- Published by Springer Science and Business Media LLC in The AAPS Journal
- Vol. 11 (2), 300-306
- https://doi.org/10.1208/s12248-009-9106-3
Abstract
Pharmacokinetic drug interactions can lead to serious adverse events, and the evaluation of a new molecular entity’s drug–drug interaction potential is an integral part of drug development and regulatory review prior to its market approval. Alteration of enzyme and/or transporter activities involved in the absorption, distribution, metabolism, or excretion of a new molecular entity by other concomitant drugs may lead to a change in exposure leading to altered response (safety or efficacy). Over the years, various in vitro methodologies have been developed to predict drug interaction potential in vivo. In vitro study has become a critical first step in the assessment of drug interactions. Well-executed in vitro studies can be used as a screening tool for the need for further in vivo assessment and can provide the basis for the design of subsequent in vivo drug interaction studies. Besides in vitro experiments, in silico modeling and simulation may also assist in the prediction of drug interactions. The recent FDA draft drug interaction guidance highlighted the in vitro models and criteria that may be used to guide further in vivo drug interaction studies and to construct informative labeling. This report summarizes critical elements in the in vitro evaluation of drug interaction potential during drug development and uses a case study to highlight the impact of in vitro information on drug labeling.Keywords
This publication has 40 references indexed in Scilit:
- Quantitative Evaluation of Pharmacokinetic Inhibition of CYP3A Substrates by Ketoconazole: A Simulation StudyThe Journal of Clinical Pharmacology, 2009
- Integrated in Vitro Analysis for the in Vivo Prediction of Cytochrome P450-Mediated Drug-Drug InteractionsDrug Metabolism and Disposition, 2008
- Application of CYP3A4 in vitro data to predict clinical drug–drug interactions; predictions of compounds as objects of interactionBritish Journal of Clinical Pharmacology, 2008
- Effect of Genetic Variation in the Organic Cation Transporter 1, OCT1, on Metformin PharmacokineticsClinical Pharmacology & Therapeutics, 2007
- Induction of drug metabolizing enzymes: A survey of in vitro methodologies and interpretations used in the pharmaceutical industry—Do they comply with FDA recommendations?Chemico-Biological Interactions, 2007
- Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin actionJCI Insight, 2007
- Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) modelsTheoretical Biology and Medical Modelling, 2007
- Relative Activation of Human Pregnane X Receptor versus Constitutive Androstane Receptor Defines Distinct Classes of CYP2B6 and CYP3A4 InducersThe Journal of pharmacology and experimental therapeutics, 2006
- Database analyses for the prediction of in vivo drug–drug interactions from in vitro dataBritish Journal of Clinical Pharmacology, 2004
- Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?AAPS PharmSci, 2002